


Formula XIV

wherein R_1 , R_2 , R_3 , R_4 , R , R_{1C} , R_{2C} , R_{3C} , R_{4C} , and n are as defined below. A common structural feature of the compounds of Formulas I, II, and XIV is the inclusion of a guanidino substituent as a

In one aspect, there is provided a compound of the Formula (I):



Formula I


wherein:

R_3 and R_4 are taken together to form a fused benzene ring, a fused pyridine ring, a fused cyclohexene ring, or a fused tetrahydropyridine ring; wherein the fused benzene ring, fused pyridine ring, fused cyclohexene ring, or fused tetrahydropyridine ring is either unsubstituted or substituted by one or more R groups;

R is selected from the group consisting of halogen, hydroxyl, alkyl, alkoxy, haloalkyl,

$-C(O)-O$ -alkyl, $-C(O)-OCH_2Ph$, $-C(O)-O$ -aryl, amino, alkylamino, and dialkylamino, aryl, arylalkylenyl, aryloxyalkylenyl, arylalkyleneoxy, aryloxy, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, heteroarylalkyleneoxy, and heteroaryloxy, wherein the alkyl, aryl, arylalkylenyl, aryloxyalkylenyl, arylalkyleneoxy, aryloxy, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, heteroarylalkyleneoxy, and heteroaryloxy groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, halogen, haloalkyl, hydroxyl, hydroxyalkylenyl, alkoxyalkylenyl, arylalkyleneoxy, nitrile, amino, alkylamino, and dialkylamino;

R_1 is selected from the group consisting of $-W-X-N(R_5)-C(=NH)-NH_2$, $-W-Z-N(R_5)-C(=NH)-NH_2$, and



;

W is selected from the group consisting of a covalent bond, -O-, and -NH-;

X is selected from the group consisting of alkylene, alkenylene, and alkynylene, wherein any of the alkylene, alkenylene, and alkynylene groups can be optionally interrupted by one or more -O- groups;

5 Z is selected from the group consisting of

-X-arylene-X-,

-X-heteroarylene-X-,

-X-arylene-, and

-X-heteroarylene-;


10 R₂ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, -O-alkyl, hydroxyalkylenyl, alkoxyalkylenyl, alkylaminoalkylenyl, hydroxyl, -CH₂-NH-O-alkyl, and -CH₂NHC(O)-alkyl;

R₅ is selected from the group consisting of hydrogen, alkyl, arylalkylenyl, alkoxyalkylenyl, aryloxyalkylenyl, benzyloxyalkylenyl, aryl-(CH₂)₂₋₆-O-alkylenyl, and cycloalkylalkylenyl, wherein
15 any of the alkyl, arylalkylenyl, alkoxyalkylenyl, aryloxyalkylenyl, benzyloxyalkylenyl, aryl-(CH₂)₂₋₆-O-alkylenyl, and cycloalkylalkylenyl groups can be either unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, alkoxy, alkyl, haloalkyl, and nitrile;

Q is selected from the group consisting of a bond, -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-,
20 -CH₂CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂CH₂-, -CH₂-O-CH₂-, and -OCH₂-;
or a pharmaceutically acceptable salt thereof.

In addition, more specific examples of such compounds include the compounds of Formulas III-XIII and Formulas XV-XVIII which are defined below, as well as salts, particularly
pharmaceutically acceptable salts, thereof.

25 In another aspect, there is provided a compound of the Formula XIII:



Formula XIII

wherein:

R_{1B} is selected from the group consisting of -X_B-N(R_{5B})-C(=NH)-NH₂,

-Z_B-N(R_{5B})-C(=NH)-NH₂, and

neoplastic disease in an animal by administering to the animal one or more compounds of the Formulas I-XVIII, and/or pharmaceutically acceptable salts thereof are also disclosed.

In another aspect, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a compound or salt as defined herein in combination with a pharmaceutically acceptable carrier.

In another aspect, there is provided use of a compound of salt as defined herein in the manufacture of a medicament for the treatment of a disease selected from the group consisting of a viral disease, a neoplastic disease, a T_H2 -mediated atopic disease, a disease associated with wound repair and a parasitic disease.

Methods for synthesizing compounds of Formulas I-XVIII are provided.

The above summary is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. In several places throughout the description, guidance is provided through lists of examples, which can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be interpreted as an exhaustive list.

DETAILED DESCRIPTION

As used herein, “a”, “an”, “the”, “at least one”, and “one or more” are used interchangeably and are intended to include both the singular and the plural except in cases where the singular alone is specifically called for or clearly required by the context.

20. A compound or salt of claim 1 for use in inducing biosynthesis of IFN-alpha.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

5

22. Use of a compound of salt of claim 1 in the manufacture of a medicament for the treatment of a disease selected from the group consisting of a viral disease, a neoplastic disease, a T_H2 -mediated atopic disease, a disease associated with wound repair and a parasitic disease.